A tragic incident in Nagpur has raised serious public health concerns after a 3-year-old girl from Chhindwara, Madhya Pradesh, died following the consumption of Coldrif cough syrup. The child was admitted to a Nagpur hospital but could not be saved, increasing the death toll from this spurious cough syrup in Madhya Pradesh to 24 as of October 16, 2025. Investigations have linked the fatalities to Sresan Pharmaceuticals, the manufacturer of the contaminated syrup. Authorities have arrested a woman chemical analyst associated with the company in connection with the case. The arrest is part of a wider crackdown on negligence and illegal practices surrounding the production and quality control of medicines. The Health Department of Madhya Pradesh, in coordination with the Food and Drug Administration (FDA), is conducting a thorough probe to identify lapses and ensure accountability. Medical experts and consumer rights activists have called for stricter monitoring of pharmaceutical companies and more rigorous drug testing protocols to prevent such incidents. Public awareness campaigns are also being intensified to caution parents about the source and usage of over-the-counter medicines. The case has reignited debates on pharmaceutical regulation and the need for swift legal and administrative action to safeguard public health. #NagpurHospital #ColdrifCoughSyrup #ChhindwaraTragedy
The Maharashtra Food and Drug Administration (FDA) has confirmed that the controversial ‘Coldrif’ cough syrup, recently banned in Tamil Nadu following child fatalities, did not enter the Maharashtra market. The clarification, issued on October 5, 2025, comes amid growing public concern over the spread of unsafe pharmaceutical products across state borders. Maha FDA officials stated that after an extensive inspection of wholesalers, distributors, and pharmacies, no consignments of the product were found within the state. The department also directed local drug inspectors to remain alert and monitor for any unauthorized shipments that might attempt to bypass state-level restrictions. The confirmation aims to reassure consumers and prevent panic, particularly among parents concerned about children’s safety. The agency further announced plans to tighten surveillance and improve inter-state coordination with health departments to prevent the circulation of potentially hazardous drugs. Meanwhile, public health experts have called for a nationwide review of pediatric medicines and over-the-counter formulations, emphasizing stricter quality control to ensure that such incidents do not recur. #MaharashtraFDA #ColdrifCoughSyrup #DrugSafety #PublicHealth #ChildSafety #PharmaRegulation #HealthNews #MedicalSafety #QualityControl #IndiaHealth
